RT Journal Article
SR Electronic
T1 Combined Use of <sup>99m</sup>Tc-Sestamibi and <sup>99m</sup>Tc-V-DMSA in the Assessment of Chemotherapy Effectiveness in Patients with Multiple Myeloma
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 978
OP 982
VO 46
IS 6
A1 John Koutsikos
A1 Theodoros Athanasoulis
A1 Athanasios Anagnostopoulos
A1 Antigone Velidaki
A1 Marianthi Passadi
A1 Meletios Athanasios Dimopoulos
A1 Cherry Zerva
YR 2005
UL http://jnm.snmjournals.org/content/46/6/978.abstract
AB This study determined the role of the combined use of 99mTc-sestamibi and 99mTc-pentavalent dimercaptosuccinic acid (V-DMSA) scintigraphy in evaluating the effectiveness of chemotherapy in patients with multiple myeloma. Methods: In 20 patients with multiple myeloma who had received or were receiving chemotherapy, 99mTc-sestamibi and 99mTc-V-DMSA scanning was performed to evaluate the effectiveness of chemotherapy. Results: In group A (11 patients with active disease), 42 99mTc-sestamibi–positive lesions were found. Thirty-seven of those lesions were also positive for 99mTc-V-DMSA uptake, as were 16 additional lesions (nonactive) (NAL). Thus, in group A, the total number of positive lesions (TPL) detected was 58 and the NAL/TPL ratio was 16:58. In group B (9 patients in remission), 5 99mTc-sestamibi–positive lesions were found. A further 22 lesions were also positive for 99mTc-V-DMSA uptake. Thus, in group B, the NAL/TPL ratio was 22:27. Therefore, the NAL/TPL ratios considered to represent effectively treated lesions were 27.6% and 81.5% for groups A and B, respectively. Conclusion: Combined use of the 2 agents allows the effectiveness of chemotherapy to be evaluated through a comparison of NAL and TPL multiple myeloma lesions even in the absence of a baseline study.